Lyell Immunopharma Stock Income Statements

Lyell Immunopharma Quarterly Income Statements Chart

Quarterly

Annual

Revenue

Operating Profit

Net Income

Lyell Immunopharma Quarterly Income Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30

revenue	8,000	7,000	11,000	34,000	13,000	3,000	13,000	25,000	27,000	65,000	48,386,000	3,000	35,741,000	553,000	2,822,000	2,755,000	2,628,000
yoy	-38.46%	133.33%	-15.38%	36.00%	-51.85%	-95.38%	-99.97%	733.33%	-99.92%	-88.25%	1614.60%	-99.89%	1260.01%
qoq	14.29%	-36.36%	-67.65%	161.54%	333.33%	-76.92%	-48.00%	-7.41%	-58.46%	-99.87%	1612766.67%	-99.99%	6363.11%	-80.40%	2.43%	4.83%
operating expenses:
research and development	34,857,000	43,447,000	48,668,000	39,500,000	40,261,000	43,174,000	46,995,000	43,849,000	47,471,000	44,630,000	38,032,000	41,607,000	43,719,000	35,830,000	19,285,000	31,433,000	46,446,000
general and administrative	9,786,000	14,046,000	14,522,000	11,769,000	12,256,000	13,494,000	13,167,000	15,507,000	19,030,000	19,279,000	26,348,000	26,084,000	30,454,000	34,421,000	31,873,000	21,241,000	19,112,000
other operating income (income)	1,062,000
impairment of long-lived assets	1,443,000
total operating expenses	47,148,000	57,374,000	201,158,000	50,539,000	51,541,000	55,578,000	59,521,000	59,064,000	65,932,000	62,621,000	63,170,000	66,440,000	73,002,000	69,129,000	50,360,000	51,916,000	65,335,000
income from operations	-47,140,000	-57,367,000	-201,147,000	-50,505,000	-51,528,000	-55,575,000	-59,508,000	-59,039,000	-65,905,000	-62,556,000	-14,784,000	-66,437,000	-37,261,000	-68,576,000	-47,538,000	-49,161,000	-62,707,000
yoy	-8.52%	3.22%	238.02%	-14.45%	-21.81%	-11.16%	302.52%	-11.14%	76.87%	-8.78%	-68.90%	35.14%	-40.58%
qoq	-17.83%	-71.48%	298.27%	-1.99%	-7.28%	-6.61%	0.79%	-10.42%	5.35%	323.13%	-77.75%	78.30%	-45.66%	44.26%	-3.30%	-21.60%
operating margin %	-589250.00%	-819528.57%	-1828609.09%	-148544.12%	-396369.23%	-1852500.00%	-457753.85%	-236156.00%	-244092.59%	-96240.00%	-30.55%	-2214566.67%	-104.25%	-12400.72%	-1684.55%	-1784.43%	-2386.11%
interest income	3,276,000	3,862,000	4,920,000	5,965,000	6,364,000	6,819,000	7,084,000	6,608,000	5,264,000	4,497,000	3,453,000	2,251,000	952,000	397,000	323,000	270,000	218,000
other income	1,180,000	1,310,000	4,292,000	-43,000	-645,000	1,090,000	-506,000	1,578,000	-326,000	1,100,000	2,934,000	-1,068,000	-14,000	35,000	-44,000	16,000	-106,000
impairment of other investments						-13,001,000			-2,923,000	-10,000,000		-5,000,000
total other income	4,456,000	5,172,000	9,212,000	5,922,000	5,719,000		6,578,000	8,186,000	2,015,000	-4,403,000	6,387,000	-3,817,000	938,000	432,000
net income	-42,684,000	-52,195,000	-191,935,000	-44,583,000	-45,809,000	-60,667,000	-52,930,000	-50,853,000	-63,890,000	-66,959,000	-8,397,000	-70,254,000	-36,323,000	-68,144,000	-83,706,000	-48,875,000	-62,595,000
yoy	-6.82%	-13.96%	262.62%	-12.33%	-28.30%	-9.40%	530.34%	-27.62%	75.89%	-1.74%	-89.97%	43.74%	-41.97%
qoq	-18.22%	-72.81%	330.51%	-2.68%	-24.49%	14.62%	4.08%	-20.41%	-4.58%	697.42%	-88.05%	93.41%	-46.70%	-18.59%	71.27%	-21.92%
net income margin %	-533550.00%	-745642.86%	-1744863.64%	-131126.47%	-352376.92%	-2022233.33%	-407153.85%	-203412.00%	-236629.63%	-103013.85%	-17.35%	-2341800.00%	-101.63%	-12322.60%	-2966.19%	-1774.05%	-2381.85%
other comprehensive loss:
net unrealized gain on marketable securities	-101,000		-469,000	1,157,000	7,000	-310,000	1,087,000	1,198,000	1,500,000	3,720,000					-1,558,000	-138,000	-90,000
comprehensive loss	-42,785,000	-52,328,000	-192,404,000	-43,426,000	-45,802,000	-60,977,000	-51,843,000	-49,655,000	-62,390,000	-63,239,000	-6,000,000	-71,899,000	-38,074,000	-73,121,000
net income per common share, basic and diluted1	-2,890
weighted-average shares used for eps calculation	14,793,000	295,098,000	261,480,000	256,309,000	255,398,000	254,252,000	250,983,000	251,318,000	250,204,000	249,591,000	247,080,000	248,320,000	246,312,000	244,178,000	135,918,000	239,384,000	42,713,000
other operating income		-119,000	-513,000	-730,000	-976,000	-1,090,000	-641,000	-292,000	-569,000	-1,288,000	-1,210,000	-1,251,000	-1,171,000	-1,122,000	-798,000	-758,000	-223,000
net unrealized loss on marketable securities		-133,000									2,397,000	-1,645,000	-1,751,000	-4,977,000
net income per common share, basic and diluted		-180	-720	-170	-180	-240	-200	-200	-260	-270	-30	-280	-150	-280	-180	-200	-1,470
total other loss						-5,092,000
comprehensive loss:
operating expenses
other comprehensive gain:
net comprehensive loss															-41,708,500	-49,013,000	-62,685,000
net income attributed to common stockholders:
deemed dividends upon repurchase of convertible preferred stock
net income attributed to common stockholders															-83,706,000	-48,875,000	-62,595,000

We provide you with 20 years income statements for Lyell Immunopharma stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Lyell Immunopharma stock. Explore the full financial landscape of Lyell Immunopharma stock with our expertly curated income statements.

The information provided in this report about Lyell Immunopharma stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.